Read the full article at Business Insider.
Two top FDA officials with over 40 years of experience at the FDA (Dr. Marion Gruber and Dr. Philip Krause, who each say that they plan to resign due to disagreements over the rollout of vaccines – head of Emergency Response, and head of Research and Development), resigned from the FDA, and will leave their positions in October. Shortly after the resignation announcement, their names appeared as authors on an article published in the prestigious Lancet journal:
Considerations in boosting COVID-19 vaccine immune responses – read the article at The Lancet.
“there could be risks if boosters are widely introduced too soon, or too frequently, especially with vaccines that can have immune-mediated side-effects (such as myocarditis, which is more common after the second dose of some mRNA vaccines,3 or Guillain-Barre syndrome, which has been associated with adenovirus-vectored COVID-19 vaccines4). If unnecessary boosting causes significant adverse reactions, there could be implications for vaccine acceptance that go beyond COVID-19 vaccines. Thus, widespread boosting should be undertaken only if there is clear evidence that it is appropriate.”
“Careful and public scrutiny of the evolving data will be needed to assure that decisions about boosting are informed by reliable science more than by politics.”
On Friday, September 16, 2021 VRBPAC will meet to discuss the approval of the third Pfizer COVID-19 shot.